Experts address lab monitoring of isotretinoin for treating acne

Experts address lab monitoring of isotretinoin for treating acne

In a consensus statement published online June 15 in JAMA Dermatology, data is provided for optimizing laboratory monitoring of acne patients treated with isotretinoin.

Eric Xia, from Harvard Medical School in Boston, and colleagues established a consensus for isotretinoin laboratory monitoring among clinical and research experts in acne. Four rounds of electronic surveys were administered from 2021 to 2022 using a modified electronic Delphi process. For reaching consensus (≥70 percent agreement) for inclusion, in subsequent rounds, questions regarding more time-specific monitoring throughout isotretinoin therapy were asked. The 22 experts had a mean of 23.7 years in practice, and represented a variety of practice settings.

The researchers found that consensus about testing or not testing was achieved for checking within a month prior to initiation (89.5 percent) and at peak dose (89.5 percent), but not monthly (76.2 percent) or after treatment completion (73.7 percent), and for checking triglycerides within a month prior to initiation and at peak dose (89.5 and 78.9 percent, respectively), but not monthly or after treatment completion (84.2 and 73.7 percent, respectively). Consensus was also achieved for not checking complete blood cell count or basic metabolic panel parameters at any point during isotretinoin treatment (all >70 percent), and for not checking gamma-glutamyl transferase, bilirubin, albumin, total protein, , , or C-reactive protein (78.9, 81.0, 72.7, 72.7, 73.7, 73.7, and 77.3 percent, respectively).

"Reducing unnecessary laboratory monitoring may help decrease the pain, fear, and direct and indirect costs experienced by patients being treated with isotretinoin for acne," the authors write.

Several authors disclosed financial ties to the pharmaceutical industry.

Explore further

Isotretinoin does not up suicide risk in acne patients

More information: Eric Xia et al, Isotretinoin Laboratory Monitoring in Acne Treatment, JAMA Dermatology (2022). DOI: 10.1001/jamadermatol.2022.2044
Journal information: JAMA Dermatology

Copyright © 2022 HealthDay. All rights reserved.

Citation: Experts address lab monitoring of isotretinoin for treating acne (2022, June 29) retrieved 7 August 2022 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Feedback to editors